EHA 2023 | Long-term follow-up from the OITI trial: ponatinib in patients with CML in Italy

Massimo Breccia • 13 Jun 2023

EHA 2023

OITI

Massimo Breccia, MD, Sapienza University of Rome, Rome, Italy, discusses the long-term follow-up of the OITI trial, a retrospective observational cohort study investigating the efficacy and safety of ponatinib in patients with chronic phase (CP), accelerated phase (AP) or blast phase (BP) chronic myeloid leukemia (CML). This real-world analysis showed that ponatinib confirmed a favorable efficacy in terms of complete cytogenetic response (CCyR) and major molecular response (MMR), and no new safety signals were reported. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.